DE602005010421D1 - Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen - Google Patents

Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen

Info

Publication number
DE602005010421D1
DE602005010421D1 DE602005010421T DE602005010421T DE602005010421D1 DE 602005010421 D1 DE602005010421 D1 DE 602005010421D1 DE 602005010421 T DE602005010421 T DE 602005010421T DE 602005010421 T DE602005010421 T DE 602005010421T DE 602005010421 D1 DE602005010421 D1 DE 602005010421D1
Authority
DE
Germany
Prior art keywords
protease inhibitors
therapeutic applications
cysteine protease
new cysteine
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005010421T
Other languages
English (en)
Inventor
Philippe Guedat
Guillaume Boissy
Catherine Borg-Capra
Frederic Colland
Laurent Daviet
Etienne Formstecher
Xavier Jacq
Jean-Christophe Rain
Remi Delansorne
Stefania Vallese
Matteo Colombo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybrigenics SA
Original Assignee
Hybrigenics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrigenics SA filed Critical Hybrigenics SA
Publication of DE602005010421D1 publication Critical patent/DE602005010421D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE602005010421T 2005-08-05 2005-08-05 Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen Active DE602005010421D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05291683A EP1749822B1 (de) 2005-08-05 2005-08-05 Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen

Publications (1)

Publication Number Publication Date
DE602005010421D1 true DE602005010421D1 (de) 2008-11-27

Family

ID=35583351

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005010421T Active DE602005010421D1 (de) 2005-08-05 2005-08-05 Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen

Country Status (4)

Country Link
EP (1) EP1749822B1 (de)
CN (1) CN101282946B (de)
AT (1) ATE411300T1 (de)
DE (1) DE602005010421D1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN02549A (de) * 2009-09-16 2015-09-04 Yissum Res Dev Co
US20110177105A1 (en) 2010-01-15 2011-07-21 Roman Lopez Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications
CN103562208B (zh) 2011-03-15 2016-08-31 默沙东公司 三环促旋酶抑制剂
EP2565186A1 (de) 2011-09-02 2013-03-06 Hybrigenics S.A. Spezifische und reversible Inhibitoren von ubiquitinspezifischer Protease 7
HUE041816T2 (hu) * 2011-10-19 2019-05-28 Vivolux Ab Módszer deubikitinációs aktivitás gátlására
BR112014018524B1 (pt) * 2012-01-27 2023-03-28 Universite De Montreal Derivados de pirimido [4,5-b]indol, seu usos, composição farmaceutica, e método in vivo ou ex vivo para aumen-tar as células estaminais e/ou progenitoras
WO2016165007A1 (en) * 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
CN111995589B (zh) 2015-11-10 2023-12-05 国立大学法人九州大学 2,5－二氰基－3,6－二卤代吡嗪的制造方法
AU2017291842A1 (en) * 2016-07-06 2019-01-17 Board Of Regents, The University Of Texas System Human-enzyme mediated depletion of cystine
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
GB202200753D0 (en) 2022-01-21 2022-03-09 Almac Discovery Ltd Pharmaceutical compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0798508B2 (ja) 1985-05-01 1995-10-25 ヤマハ発動機株式会社 小型船舶の船体構造
JP3219339B2 (ja) 1993-06-15 2001-10-15 株式会社リコー ピラジン化合物及びそれを含有する電子写真感光体
JPH07175235A (ja) 1993-12-20 1995-07-14 Ricoh Co Ltd 単層型電子写真用感光体
JP3255525B2 (ja) 1993-12-23 2002-02-12 株式会社リコー ピラジン化合物及びそれを含有する電子写真感光体
JPH07199486A (ja) 1993-12-30 1995-08-04 Ricoh Co Ltd 電子写真用感光体
JPH07199487A (ja) 1993-12-30 1995-08-04 Ricoh Co Ltd 電子写真用感光体
JPH07281460A (ja) 1994-04-14 1995-10-27 Ricoh Co Ltd 潜像転写用電子写真感光体
JP4099237B2 (ja) * 1996-12-11 2008-06-11 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト カルパインインヒビターとしてのケトベンズアミド
JP2000128885A (ja) 1998-10-19 2000-05-09 Ricoh Co Ltd テトラピラジノポルフィラジン化合物及びその製造方法
JP2000122316A (ja) 1998-10-19 2000-04-28 Ricoh Co Ltd 電子写真感光体
AU2002305926A1 (en) * 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
US20040232954A1 (en) 2001-07-06 2004-11-25 Van Zeijl Paulus Thomas Signal generator device, method for generating a signal and devices including such a signal generator device
JP2005517640A (ja) * 2001-12-04 2005-06-16 エフ．ホフマン−ラ　ロシュ　アーゲー 置換２−アミノ−シクロアルカンカルボキサアミドならびにシステインプロテアーゼインヒビターとしてのその使用
EP1537074B1 (de) * 2002-09-04 2019-02-27 Merck Canada Inc. Cathepsin-cystein-protease-inhibitoren

Also Published As

Publication number Publication date
EP1749822A1 (de) 2007-02-07
CN101282946B (zh) 2013-08-14
CN101282946A (zh) 2008-10-08
ATE411300T1 (de) 2008-10-15
EP1749822B1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
DE602005010421D1 (de) Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen
MA29135B1 (fr) Potentialisateurs de recepteurs du glutamate
CY1112630T1 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
CY1114916T1 (el) Μεθοδοι
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
EA200701467A1 (ru) Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
SE0201976D0 (sv) Novel compounds
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
EA200602281A1 (ru) Гетероарилсульфоны и сульфонамиды и их терапевтические применения
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
ATE411287T1 (de) Neue metallproteinaseinhibitoren
DE602006020585D1 (de) Neue cysteinproteasehemmer und ihre therapeutische anwendung
EA200801139A1 (ru) Композиция для аэрозольной ингаляции
MX2008007195A (es) Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas.
EA200701881A1 (ru) 1,3-тиазол-5-карбоксамиды, используемые в качестве противораковых химиотерапевтических агентов
UA95930C2 (uk) Інгібітори цистеїнпротеаз, фармацевтична композиція, яка їх містить, та їх терапевтичне застосування
CY1115764T1 (el) Αναστολεις iap
EA200801392A1 (ru) Соединения 4-оксадиазолил-пиперидина и их применение
TH103186B (th) โปรดรักเอไมด์ของเจมไซทาบีน, สารผสมและการใช้ของสิ่งนั้น

Legal Events

Date Code Title Description
8364 No opposition during term of opposition